Explore Bladder Cancer Studies
ABLE-32
AUA IR NMIBC (including HG <3cm) will be randomized to Adstiladrin (intravesc 1x q3mo) vs observation. Patients on observation who have an IR recurrence can crossover to treatment.
AUA-Intermediate
Protara III
BCG naïve (or no BCG in last 2yrs or 2 or fewer doses of BCG in the last 2yrs) CIS +/- papillary disease. Patients are randomized to TARA-002 (which is similar to BCG but composed of strep pyogenes) vs intravesical chemo – both given via induction and maintenance. Crossover allowed.
CORE-8 (Paused Enrollment)
Cohort B – HR BCG exposed patients with CIS or papillary disease, all patients will have Cretostimogene
Protara Advanced 2
BCG unresponsive (by the FDA definition, must have had at least 5 of 6 induction rounds and 2 of 3 maintenance or 2 of 6 reinduction) CIS. All patients will have TARA-002 which is similar to BCG but composed of strep pyogenes – given via induction and maintenance.
AUA - High Risk
Merck V940
A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
BCG Intolerant and CIS